3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
3
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
5
Recurrence
4
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hematologic Neoplasms
1
Interventions
Rituximab
45
Cyclophosphamide
32
fludarabine phosphate
28
fludarabine
19
ibrutinib
17
Peripheral Blood Stem Cell Transplantation
17
Lenalidomide
17
venetoclax
13
Mycophenolic Acid
10
Cyclosporine
10
acalabrutinib
9
Whole-Body Irradiation
9
Filgrastim
9
obinutuzumab
7
Bendamustine Hydrochloride
7
Antilymphocyte Serum
7
Radiotherapy
6
Methotrexate
6
Melphalan
6
Prednisone
5
Etoposide
5
Busulfan
5
zanubrutinib
4
pirtobrutinib
4
aldesleukin
4
Vincristine
4
Tacrolimus
4
Indium
4
Immunotherapy, Adoptive
4
Granulocyte Colony-Stimulating Factor
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
tafasitamab
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts